Clinical and Treatment Determinant of Prognosis in Glioblastoma

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07197086

Enrollment

Registered

2025-09-29

Start date

2025-10-01

Completion date

2026-12-01

Last updated

2025-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioblastoma

Brief summary

Gliomas represent the most common primary malignant brain tumors in adults, with glioblastoma (WHO grade 4) being the most aggressive subtype. Despite advances in surgical techniques, radiotherapy, and chemotherapy, prognosis remains poor, particularly for high-grade gliomas. Maximal safe surgical resection is considered a cornerstone in the management of gliomas. Several studies suggest that a greater extent of resection (EOR) is associated with improved overall survival (OS) and progression-free survival (PFS), particularly in high-grade tumors. However, the benefit must be balanced against the risk of neurological deficits. Postoperative chemoradiotherapy, particularly with temozolomide, has become the standard of care for high-grade gliomas. Despite this, the impact of EOR on outcomes in the context of adjuvant chemoradiotherapy remains a subject of ongoing investigation. This study aims to evaluate the prognostic significance of the extent of surgical resection in glioma patients who undergo postoperative chemoradiotherapy.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adult patients (≥18 years) with histologically confirmed glioma (WHO grades 2-4) Underwent neurosurgical resection (gross total, subtotal, or biopsy only) Received postoperative radiotherapy with or without concurrent and/or adjuvant temozolomide Available pre- and post-operative imaging for EOR assessment Complete medical records and follow-up data

Exclusion criteria

* Recurrent gliomas at presentation Incomplete treatment (e.g., abandonment, death before adjuvant therapy) Lack of imaging or follow-up data

Design outcomes

Primary

Measure	Time frame	Description
Overall survival	5 years	Overall survival (from surgery to death/last follow-up )which defined as the length of time from either the date of diagnosis or the start of treatment that patients diagnosed with the disease are still alive

Outcome results